These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36860876)

  • 1. Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients.
    Petrova V; Groth C; Bitsch R; Arkhypov I; Simon SCS; Hetjens S; Müller V; Utikal J; Umansky V
    Front Immunol; 2023; 14():1065767. PubMed ID: 36860876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.
    Sun SH; Benner B; Savardekar H; Lapurga G; Good L; Abood D; Nagle E; Duggan M; Stiff A; DiVincenzo MJ; Suarez-Kelly LP; Campbell A; Yu L; Wesolowski R; Howard H; Shah H; Kendra K; Carson WE
    Front Immunol; 2021; 12():740890. PubMed ID: 34712230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling.
    Arkhypov I; Özbay Kurt FG; Bitsch R; Novak D; Petrova V; Lasser S; Hielscher T; Groth C; Lepper A; Hu X; Li W; Utikal J; Altevogt P; Umansky V
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
    Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A
    Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis.
    Möller M; Orth V; Umansky V; Hetjens S; Braun V; Reißfelder C; Hardt J; Seyfried S
    Front Immunol; 2024; 15():1403771. PubMed ID: 38855104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling.
    Özbay Kurt FG; Cicortas BA; Balzasch BM; De la Torre C; Ast V; Tavukcuoglu E; Ak C; Wohlfeil SA; Cerwenka A; Utikal J; Umansky V
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39266214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients.
    Adamo A; Frusteri C; Pilotto S; Caligola S; Belluomini L; Poffe O; Giacobazzi L; Dusi S; Musiu C; Hu Y; Wang T; Rizzini D; Vella A; Canè S; Sartori G; Insolda J; Sposito M; Incani UC; Carbone C; Piro G; Pettinella F; Qi F; Wang D; Sartoris S; De Sanctis F; Scapini P; Dusi S; Cassatella MA; Bria E; Milella M; Bronte V; Ugel S
    Oncoimmunology; 2023; 12(1):2253644. PubMed ID: 37720688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.
    Weber R; Fleming V; Hu X; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():1310. PubMed ID: 29942309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
    Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
    Front Immunol; 2022; 13():955063. PubMed ID: 36248850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice.
    Bitsch R; Kurzay A; Özbay Kurt F; De La Torre C; Lasser S; Lepper A; Siebenmorgen A; Müller V; Altevogt P; Utikal J; Umansky V
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35301236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
    Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
    Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma.
    Weber R; Riester Z; Hüser L; Sticht C; Siebenmorgen A; Groth C; Hu X; Altevogt P; Utikal JS; Umansky V
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
    Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
    Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer.
    Park SM; Youn JI
    Arch Pharm Res; 2019 Jul; 42(7):560-566. PubMed ID: 31147902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors.
    Simon SCS; Hu X; Panten J; Grees M; Renders S; Thomas D; Weber R; Schulze TJ; Utikal J; Umansky V
    Oncoimmunology; 2020; 9(1):1727116. PubMed ID: 32117594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
    Gaißler A; Bochem J; Spreuer J; Ottmann S; Martens A; Amaral T; Wagner NB; Claassen M; Meier F; Terheyden P; Garbe C; Eigentler T; Weide B; Pawelec G; Wistuba-Hamprecht K
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target.
    Ozbay Kurt FG; Lasser S; Arkhypov I; Utikal J; Umansky V
    J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37395271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
    Chung JS; Ramani V; Kobayashi M; Fattah F; Popat V; Zhang S; Cruz PD; Gerber DE; Ariizumi K
    Clin Cancer Res; 2020 Mar; 26(6):1449-1459. PubMed ID: 31822499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.
    Lepper A; Bitsch R; Özbay Kurt FG; Arkhypov I; Lasser S; Utikal J; Umansky V
    Oncoimmunology; 2023; 12(1):2247303. PubMed ID: 37593676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade.
    Mukherjee N; Katsnelson E; Brunetti TM; Michel K; Couts KL; Lambert KA; Robinson WA; McCarter MD; Norris DA; Tobin RP; Shellman YG
    Cell Death Dis; 2024 Mar; 15(3):198. PubMed ID: 38459020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.